Lanreotide: Uses, Mechanism, Evidence, and Side Effects

Patients managing acromegaly or certain neuroendocrine tumors often want to know how their treatment works and what the evidence actually supports. Lanreotide is a long-studied injectable therapy with a well-defined role in these conditions.

Key takeaways

• Lanreotide is a somatostatin analog marketed as Lanreotide Acetate.
• It is approved for acromegaly, certain gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.
• More than 125 registered clinical trials have studied lanreotide, including phase 3 and phase 4 work.
• The most frequently reported adverse events in safety reports are diarrhoea, fatigue, and nausea.
• Lanreotide's label does not carry a boxed warning.

What Lanreotide Is

Lanreotide is an octapeptide analog of natural somatostatin, a hormone the body uses to regulate hormone and cell growth signaling. Its mechanism of action is believed to mirror that of natural somatostatin, meaning it works by activating the same biological pathways the body already uses to dampen excess hormone secretion and cell proliferation. It is identified in chemical databases under PubChem CID 6918011.

What Lanreotide Is Approved For

Lanreotide, sold as Lanreotide Acetate, has three approved uses. It is indicated for long-term treatment of acromegaly in patients who have not adequately responded to, or cannot undergo, surgery and/or radiotherapy. It is also approved for adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), where it is used to improve progression-free survival. Additionally, it is approved for adults with carcinoid syndrome, where it reduces how often patients need short-acting somatostatin analog rescue therapy. The label does not carry a boxed warning.

What the Evidence Shows

Lanreotide has been studied in 126 registered clinical trials. Among these, a completed phase 3 trial compared different doses of Lanreotide Autogel against a prolonged-release formulation in patients with acromegaly. A completed phase 4 study examined self- and partner-administered injection of Somatuline Autogel in the acromegaly population, reflecting real-world use patterns beyond initial approval trials.

Reported Side Effects

Safety reports submitted to FAERS show gastrointestinal effects as the most common concern, led by diarrhoea (1,440 reports), nausea (735), and abdominal pain (573). Fatigue (983 reports) and injection site pain (601) are also frequently reported, along with headache (507). A substantial number of reports (1,514) describe off-label use, and some reports (1,278) list death, though FAERS counts reflect submitted reports rather than confirmed incidence or causation.